The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Otsuka Pharmaceutical Netherlands B.V.EU/1/18/1294/006

Main Information

Trade NameRXULTI
Active SubstancesBrexpiprazole
Dosage FormFilm-coated tablet
Licence HolderOtsuka Pharmaceutical Netherlands B.V.
Licence NumberEU/1/18/1294/006

Group Information

ATC CodeN05AX16 brepiprazole


License statusAuthorised
Licence Issued26/07/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back